ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 83

Substantial Functional Disability Is the Key Determinant of Discrepancies Between EQ-5D and SF-6D Utility Measures in Early Arthritis: Results From the Espoir Cohort

Cécile Gaujoux-Viala1, Bruno Fautrel2, Kossar Hosseini3, Francis Guillemin4, René-Marc Flipo5 and Anne-Christine Rat3, 1Rheumatology, Montpellier I University, Nîmes University Hospital, Nîmes, France, 2Rheumatology, UPMC - Paris 6 University, Paris, France, 3CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 4Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, F- 54 000, Nancy, France, 5Rheumatology Department, Lille University Hospital, Lille, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The EQ-5D, a 5-dimensional multi-attribute questionnaire, and the SF-6D, derived from the SF36, are 2 indirect utility measures widely used to calculate quality-adjusted life-years in order to assess health benefits.

Objective: 1) To assess which variables at baseline are associated with EQ-5D and SF-6D in early arthritis 2) To assess which variables at baseline are associated with substantial utility differences between EQ-5D and SF-6D.

Methods: – Patients: EQ-5D and SF-6D utility measures were assessed in 813 patients included in the French nationwide ESPOIR cohort, which enrolled early arthritis (EA) patients with ≥2 swollen joints for less than 6 months and suspicion of RA.

               – Analysis:  Determinants of EQ-5D and SF-6D at baseline were assessed by multivariate linear regression. Multivariate linear regression was used to determine which aspects of EA were independently associated with the difference between the two utility measures in patients with substantial utility difference, i.e. l SF-6D – EQ5D l >0.074 (highest minimal important difference, MID).To assess the determinants of having substantial utility difference, patients were divided into 3 categories at baseline:  l SF-6D–EQ-5D l >0.074 and SF-6D>EQ-5D, l SF-6D – EQ-5D l >0.074 and EQ-5D>SF-6D and the others corresponding to no substantial difference (reference category). Variables collected at baseline were analyzed by polytomous logistic regression, with the 3 categories as dependent variables.

Results: At baseline, mean values were 0.52±0.31 (range -0.59 to 1) for EQ-5D and 0.58±0.11 (range 0.30 to 0.92) for SF-6D. In the multivariate linear regression model, higher HAQ, pain and lower mental status (AIMS2-SF) were significant determinants of a lower EQ-5D. HAQ and AIMS2-SF-mental scores explained 41.4 and 7.9% of the variance respectively. Higher HAQ, patient global evaluation, pain, fatigue, and lower mental status were significantly associated with lower SF-6D. HAQ and AIMS2-SF-mental scores explained 49.3 and 14.5% of the variance respectively.

The majority of patients presented a substantial difference between the 2 utility values>0.074 (66.5%) (mean difference 0.064 [range -0.421;0.941]). In these patients, higher disability, lower mental status and higher CRP were associated with substantial difference between EQ-5D and SF-6D. HAQ and AIMS2-SF-mental scores explained 43.3 and 2% of the variance respectively.

In the polytomous logistic regression model, HAQ, lower mental status and higher pain were associated with substantial difference between EQ-5D and SF-6D. Lower disability was associated with the probability that EQ-5D was substantially superior than SF-6D in comparison with no substantial difference. Higher disability was associated with the probability that SF-6D was substantially superior to the EQ-5D.

Conclusion: Higher functional disability is the key element leading to substantial difference between the two utility measures in EA patients. EQ-5D and SF-6D are not interchangeable especially in patients with worse functional ability and the results of cost-utility studies using different utility instruments must not be compared.


Disclosure:

C. Gaujoux-Viala,
None;

B. Fautrel,
None;

K. Hosseini,
None;

F. Guillemin,
None;

R. M. Flipo,
None;

A. C. Rat,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/substantial-functional-disability-is-the-key-determinant-of-discrepancies-between-eq-5d-and-sf-6d-utility-measures-in-early-arthritis-results-from-the-espoir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology